GenFleet Therapeutics (Shanghai) Inc.
GenFleet Therapeutics is a Shanghai-based, Hong Kong-listed (HKEX: 2595) oncology developer. Its KRAS G12C inhibitor fulzerasib (GFH925) is approved in China, and early clinical results for GFH276 were presented as an ESMO 2026 late-breaking abstract.
| Headquarters | Shanghai, China |
|---|---|
| Listing | HKEX:02595 |
| Lead asset / stage | fulzerasib (GFH925) Approved — China |
| Latest event | GenFleet presented initial GFH276 clinical results as an ESMO 2026 late-breaking abstract. |